VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Revenue of VectivBio Holding AG (VECT)
Revenue in 2022 (TTM): $27.34 M
According to VectivBio Holding AG's latest financial reports the company's current revenue (TTM) is $27.34 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of VectivBio Holding AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $27.34 M | $27.34 M | $-79,848,000 | $-93,628,000 | $-93,735,000 |
| 2021 | $ | $ | $-86,413,000 | $-86,945,000 | $-87,009,000 |
| 2020 | $ | $ | $-57,554,000 | $-59,943,000 | $-60,497,000 |
| 2019 | $ | $ | $-24,148,000 | $-23,481,000 | $-23,531,000 |